Medical Toxicologists Issue Formal Position on 7-OH: Avoid Use Outside Clinical Research

Why it matters

The ACMT is the leading organization of medical toxicologists in the U.S. Their formal position statement carries clinical weight and directly shapes how emergency physicians and poison control centers approach 7-OH exposures. It arrives precisely as the DEA moves to temporarily Schedule I the compound.

The big picture

Seven-hydroxymitragynine (7-OH) began appearing in U.S. retail markets in the late 2010s, marketed under the "kratom" label despite being far more potent than natural kratom leaf. As concentrated 7-OH products proliferated in gas stations and smoke shops, poison center calls surged and overdose deaths mounted. The DEAs July 2026 notice of intent to temporarily Schedule I both 7-OH and related synthetic derivatives like MGM-15 and MGM-16 pushed major medical societies to formalize their guidance.

Key findings

• 7-OH produces opioid-like respiratory depression in animal studies, with effects fully reversed by naloxone — consistent with mu-opioid receptor activity
• Poison center exposures related to kratom and 7-OH are projected to increase nearly 68% in 2026 compared with 2025; roughly 1 in 4 exposed patients required hospitalization
• Commercially available 7-OH products contain concentrations significantly higher than natural kratom and often exceed their own labeled content
• Buprenorphine has been used successfully to treat 7-OH dependence and withdrawal, analogous to opioid use disorder treatment
• ACMT finds no proven therapeutic benefit for 7-OH and calls for any use to occur only within formally supervised clinical research
• The DEAs July 6 notices target concentrated 7-OH above 0.05% dry weight threshold, leaving natural kratom leaf products outside the scheduling action

What they say

ACMT states: "At present, there are no proven therapeutic benefits for 7-OH and other kratom-associated compounds. Use of 7-OH should occur in the context of clinical research conducted with appropriate institutional, regulatory, and ethical oversight."

Bottom line

Americas top medical toxicology body says 7-OH is a de facto opioid with no proven medical use — clinicians should treat dependence like opioid use disorder, and the public should stay away absent a clinical trial.